NCT02518113 evaluated the combination of NOTCH1 inhibitor Crenigacestat, in association with dexamethasone in adult patients with relapsed/refractory (R/R) T-ALL/T-cell lymphoblastic lymphoma (LBL), unfortunately demonstrated limited clinical activity at the recommended dose.105. The gene discussed is NOTCH1; the disease is acute lymphoblastic leukemia.